Jolanda Howe Sells 375 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 375 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $34.00, for a total value of $12,750.00. Following the transaction, the senior vice president now directly owns 2,426 shares of the company’s stock, valued at $82,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mirum Pharmaceuticals Trading Up 0.6 %

Shares of Mirum Pharmaceuticals stock opened at $33.88 on Thursday. The company has a 50-day simple moving average of $27.01 and a two-hundred day simple moving average of $27.21. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $35.56. The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). The company had revenue of $69.22 million for the quarter, compared to analyst estimates of $69.71 million. Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.66 EPS for the current year.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MIRM. AJOVista LLC bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth about $40,000. Wetzel Investment Advisors Inc. acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $41,000. StepStone Group LP bought a new stake in Mirum Pharmaceuticals in the fourth quarter valued at approximately $135,000. China Universal Asset Management Co. Ltd. boosted its holdings in Mirum Pharmaceuticals by 447.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,394 shares of the company’s stock valued at $159,000 after acquiring an additional 4,408 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at approximately $194,000.

Analysts Set New Price Targets

Several research firms recently weighed in on MIRM. Baird R W raised shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research note on Monday, June 17th. JMP Securities lifted their price objective on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 18th. SVB Leerink cut their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research note on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $40.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 9th. Finally, Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $34.00 to $39.00 and gave the company an “outperform” rating in a research report on Monday, June 17th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $53.64.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.